EOM Pharmaceuticals Holdings, Inc.
http://www.imuc.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From EOM Pharmaceuticals Holdings, Inc.
PRIME Scheme: EMA Says Yes To Hookipa, Bluejay & 89bio But No To Six Others
Esepapogene zalarnarepvec, BJT-778 and pegozafermin are the latest investigational products that the European Medicines Agency said merited a place on its priority medicines scheme.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- ImmunoCellular Therapeutics, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice